{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:13:08Z","timestamp":1788243188266,"version":"build-2803163510"},"reference-count":0,"publisher":"Bioscientifica","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:p>Primary hyperparathyroidism (pHPT) is a common endocrine disorder that can be cured by parathyroidectomy; patients unsuitable for surgery can be treated with cinacalcet. Availability of surgery may be reduced during COVID-19, and cinacalcet can be used as bridging therapy. In this single-centre retrospective analysis, we investigated the utility and safety of cinacalcet in patients with pHPT receiving cinacalcet between March 2019 and July 2020, including pre-parathyroidectomy bridging. We reviewed and summarised the published literature. Cinacalcet dosages were adjusted by endocrinologists to achieve target calcium &lt; 2.70 mmol\/L. Eighty-six patients were identified, with the most achieving target calcium (79.1%) with a mean dose of 39.4 mg\/day (\u00b117.1 mg\/day) for a median duration of 35 weeks (1\u2013178 weeks). Calcium was normalised in a median time of 5 weeks. The majority of patients commenced cinacalcet of 30 mg\/day (78 patients) with the remainder at 60 mg\/day (8 patients). Forty-seven patients commencing lower dose cinacalcet (30 mg\/day) achieved target calcium without requiring 60 mg\/day. Baseline PTH was significantly higher in patients requiring higher doses of cinacalcet. 18.6% of patients reported adverse reactions and 4.7% discontinued cinacalcet. Patients treated with cinacalcet pre-parathyroidectomy required a higher dose and fewer achieved target calcium compared to medical treatment with cinacalcet alone. Post-operative calcium was similar to patients who were not given pre-parathyroidectomy cinacalcet. In summary, cinacalcet at an initial dose of 30 mg\/day is safe and useful for achieving target calcium in patients with symptomatic or severe hypercalcaemia in pHPT, including those treated for pre-parathyroidectomy. We propose a PTH threshold of &gt;30 pmol\/L to initiate at a higher dose of 60 mg\/day.<\/jats:p>","DOI":"10.1530\/ec-21-0258","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T11:58:06Z","timestamp":1634212686000},"page":"1435-1444","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":8,"title":["A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism"],"prefix":"10.1530","volume":"10","author":[{"given":"Daniel","family":"Bell","sequence":"first","affiliation":[{"name":"1Department of Pharmacy, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hale","sequence":"additional","affiliation":[{"name":"2Department of Endocrinology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Go","sequence":"additional","affiliation":[{"name":"2Department of Endocrinology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben G","family":"Challis","sequence":"additional","affiliation":[{"name":"2Department of Endocrinology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilak","family":"Das","sequence":"additional","affiliation":[{"name":"3Department of Radiology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Fish","sequence":"additional","affiliation":[{"name":"4Department of Head and Neck Surgery, Cambridge University NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth T","family":"Casey","sequence":"additional","affiliation":[{"name":"2Department of Endocrinology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK"},{"name":"5Department of Medical Genetics, Cambridge University, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/10\/11\/EC-21-0258.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/10\/11\/EC-21-0258.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:44:41Z","timestamp":1784555081000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/10\/11\/1435-1444\/180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":0,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.1530\/ec-21-0258","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}